Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Cryoport, Inc. CYRX

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$176.2M
▲ 12.4% YoY
$78.3M
$-25.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Cryoport, Inc. provides integrated, temperature-controlled supply chain solutions for the life sciences, with a focus on supporting the cell and gene therapy market. As of December 31, 2025, Cryoport supported 760 clinical trials and 20 commercially approved cell and gene therapies. The Company delivers its integrated life sciences services and products through three operating units. Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through specialized transport, cGMP storage, kit production, labeling, packaging, and commercial therapy fulfillment. CryoGene delivers long-term temperature-controlled BioStorage and related value-added services for preclinical and early-stage clinical programs for biopharmaceutical products. MVE Biological Solutions designs and manufactures cryogenic systems, including freezers, dewars, and transport systems, used for the storage and movement of biological materials in the life sciences.

Written from the business description in Cryoport, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth

USD 176.2M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 176.2 · Net income 78.3
100M200M-100M-200M
201020132016201920222025
Compound annual growth
−9.4%
+17.5%
+40.5%
+48.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.5% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

44 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -20.9% · Net 44.4%
-500%-1000%
201020172025
ROE
FY2025 · ROE 17.3%
-100%-200%
201020172025
Three returns, three denominators.

Each USD of equity produced 17 cents of profit this year.

Cash & shareholders

USD 6.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -25.0
-15M-30M
201020172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 6.0
15M30M-10M-20M
2020202120222025

USD 6.0M in buybacks — 8% of the year's profit went back to shareholders.

Total assetsUSD 765.0M
EquityUSD 502.6M
CashUSD 250.5M
Current ratio2.17×

Equity funds 66% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CYRX, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.20.20.20.20.20.10.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.1−0.1−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.0−0.00.00.00.00.00.00.00.00.00.00.0
Net income $B0.1−0.1−0.1−0.0−0.3−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $1.40−2.49−2.21−0.93−6.18−1.94−0.55−0.34−0.34−0.93−2.05−2.44−4.81−0.17−0.27−0.46
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %17.3−25.8−19.1−6.2−53.8−12.8−22.2−33.9−67.0−298.8————−161.9−103.4
Shares out B0.050.050.050.050.050.040.040.030.030.020.010.010.060.040.040.03

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 80 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
Data on record since2010

Share this section

Download image